ArriVent BioPharma, Inc. Common Stock
USD29.92
-0.76 (-2.48%)
CEO
Zhengbin Yao
IPO Date
2024-01-26
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$30.37
Prev. Close
$30.68
Day Low
$28.31
Day High
$30.40
52W Low
$16.10
52W High
$32.14
Market Cap
$1.39B
Volume
0.78M
| 150,000 |
| $22.67 |
| 4 Feb 2026 | Kung Winston | Chief Financial Officer | A-Award | Acquired | 140,000 | $22.67 |
| 4 Feb 2026 | Yao Zhengbin | director, officer: President and CEO | A-Award | Acquired | 550,000 | $22.67 |
| 4 Feb 2026 | Kastenmayer James Paul | General Counsel | A-Award | Acquired | 130,000 | $22.67 |
| 3 Feb 2026 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10 percent owner | S-Sale | Disposed | 555,555 | $23.37 |
| 15 Jul 2025 | LaChapelle Robin | Chief Operating Officer | M-Exempt | Acquired | 2,050 | $2.28 |
| 15 Jul 2025 | LaChapelle Robin | Chief Operating Officer | M-Exempt | Acquired | 2,600 | $2.28 |
| 15 Jul 2025 | LaChapelle Robin | Chief Operating Officer | M-Exempt | Acquired | 6,503 | $2.28 |
| 15 Jul 2025 | LaChapelle Robin | Chief Operating Officer | M-Exempt | Disposed | 2,050 | $2.28 |